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Ewing's Sarcoma is a pediatric bone cancer with a five-year survival rate of only 30%. New 
treatment options for this highly aggressive disease are desperately needed. Ajulei:nic acid (AJA), 
a synthetic cannabinoid, has been the focus of our research, and has demonstrated the ability to 
decrease tumor cell viability and inhibit endothelial cell migration and angiogenesis. Based on 
these results, AJA is a potential therapeutic agent for Ewing's Sarcoma and other solid pediatric 
cancers. In order to -create a realistic environment in vitro in which to study these tumors, we 
created 3-dimensional spheroids with three cell types, each of which fluoresces a different color. 
These include: fibroblasts, which give the spheroids a connective tissue component, endothelial 
cells, which line and form blood vessels in the body, and cancer cells. These spheroids were then 
treated with different concentrations of AJA and compared to control groups in an effort to 
understand cellular proteins and pathways being modulated by the drug. Also, in order to test 
AJA in a more realistic model of human cancer, we developed a novel bioluminescent mouse 
model of Ewing's Sarcoma. We compared luminescent to physical measurements and assessed 
the ability of AJA to decrease tumor growth in vivo. Our findings show support for AJA as a 
potential new cancer treatment option. 
Introduction 
Ewing's Sarcoma is a highly aggressive malignant tumor of the bone and soft tissues 
found in children (5). These tumors require the development of a vascular network in order to 
grow. Previous studies have shown that vascular endothelial growth factor (VEGF) supports 
angiogenesis and is up-regulated in patients with Ewing's Sarcoma. Studies have also shown that 
inhibiting VEGF activity prevents tumors from growing (7). Likewise, matrix metalloproteinase-
9 (MMP-9) has been shown to regulate angiogenesis as well as tumor growth and cell migration. 
When it is suppressed, previous studies have shown that metastasis of the tumor is inhibited (5). 
New treatment options are needed in order to increase the survival rates of patients with 
this disease. Studies have shown that cannabinoids are capable of inhibiting cancer cell growth in 
many types of cancer (3). Thus, they may be an appropriate treatment option for Ewing's 
Sarcoma. Ajulemic acid (AJA), specifically, is a synthetic non-psychoactive cannabinoid which 
shows promise as a treatment option because of its lack of adverse side effects. It also has a low 
potential for abuse, which makes it a more likely candidate for cancer treatment (1 ). Although its 
structure is similar to that of tetrahydrocannabinol (THC), the active compound found in the 
Cannibis or marijuana plant, AJA does not produce a "high" like THC at doses appropriate for 
therapy (1). Previous studies have shown that AJA has anti-inflammatory effects and is capable 
of inhibiting tumor growth in several types of cancer cells. Also, AJA had a lesser effect on 
normal, healthy cells in these studies and once treatment was stopped, normal cell growth 
resumed (1). While many cannabinoids have psychoactive properties, none have been detected in 
studies with AJA. This drug is also analgesic, more potent than other cannabinoids, and 
nontoxic, which adds to its potential as a possible cancer treatment option ( 4). 
Previous research in our lab has shown that AJA decreases cancer cell viability and 
inhibits endothelial cell migration and angiogenesis, as well as tumor cell invasion. This 
indicates that AJA may be interfering with proteins that regulate these processes, such as VEGF 
and MMP-9 respectively. Without a vascular system to nourish a tumor and carry away its waste, 
cancer cells would struggle to survive. 
In previous studies, in vivo 3-dimensional models called spheroids have been used to 
study tumors. Until recently, spheroids were made up of two cell types, cancer cells and 
endothelial cells, suspended in hanging drops of medium (6). Our current research has 
incorporated a third cell type, fibroblasts, into the spheroid in order to create an even more 
realistic in vitro model. Fibroblasts give the spheroid a connective tissue component, which is 
more representative of the environment a tumor is exposed to in a living organism. Each of the 
three different cell types used in our spheroids were transfected to fluoresce a different color. 
This will enable us to keep track of the different cell types when the spheroids are treated with 
AJA. By treating the spheroids with AJA, we have also studied its effects on the expression of 
some of the proteins necessary for tumor survival and progression, such as VEGF and MMP-9. 
Animal models are necessary in order to more accurately study the effects of AJA on 
Ewing's Sarcoma. Thus, we have developed a novel intratibial bioluminescent mouse model of 
Ewing's Sarcoma to serve as a more realistic version of the disease found in humans. Tumors 
can be grown in the bone, as they grow in children, and the growth and regression of tumors can 
be measured through the intensity of light produced by the tumor cells. The cancer cells created 
for this model express high levels of luciferase (2), the enzyme that ·Catalyzes the reaction 
allowing fireflies to light up. Therefore, when the cells are exposed to luciferin, the substrate for 
the reaction, they luminesce. In these experiments, we implanted the tumor ·cells subcutaneously 
and made both physical and luminescent measurements. We hypothesized that physical 
measurements would correlate with luminescent measurements, demonstrating that our 
bioluminescent intratibial model is a solid model in which to study Ewing's sarcoma. We also 
studied the ability of AJA to decrease tumor growth in the mice when used at varying 
concentrations. 
Materials and Methods 
MTT Assay on TC71-PM4-GR cells 
TC71-PM4-GR cells (a generous gift from E.S.Kleinerman, University of Texas, M.D. 
Anderson Cancer Center), which are Ewing's sarcoma cells taken from secondary lung tumors, 
were plated in a 24-well plate and treated with 16j.!M, 32j.!M, and 64j.!M AJA. We used these 
concentrations because the LD50 ofSK-ES cells, a primary Ewing's line in which all initial 
experiments were completed, when treated with AJA is 32j.!M. Some of the cells were also left 
untreated. 72 hours after treatment, growth media was aspirated. MTT was added as a 1:50 
mixture in minimum essential medium with L-glutamine (Gibco Life Technologies). The plate 
was then incubated for 1 to 2 hours and the media was aspirated. Cells were solubilized in 0.5mL 
DMSO and plates were rocked for 15 minutes at room temperature. Absorbance was measured at 
570nM. 
MTS Assay on TC71-P M4-GR cells 
TC71-PM4-GR cells were plated into 96-well plates and treated with l6j.!M, 32j.!M, and 
64j.!M AJA. Some of the wells were also left untreated. 72 hours after treatment, an MTS assay 
was run according to the manufacturer's recommendations (Promega). 
Spheroids 
In order to provide a moist environment for the spheroids, O.SmL of PBS were pipetted 
into each well of a 48-well plate. Cells were then counted. For spheroids containing 2 cell-lines, 
1,500 cells were needed for each cell-line. For spheroids containing 3 cell-lines, 1,000 cells were 
needed for each cell line. All spheroids contain a total of 3000 cells in a final volume of 20111. 
Spheroids containing 2 cell-lines were made up ofTC71-PM4-GR cells and EAhy-RED cells. 
Spheroids containing 3 cell-lines were made up ofTC71-PM4-GR cells, WI-38 cells, and EPC 
cells. The cell suspension was pipetted onto the middle of the circle on the lid of a 48-well plate, 
and the lid was carefully flipped and placed over the well plate containing PBS. The plate was 
then incubated at 37°C for 6 days. Spheroids were treated with 10flM, 20flM, and 32flM AJA. 
Control wells were untreated. 
ELISA assay for VEGF and MMP-9 
Media samples from spheroids were removed 18 hours post-treatment and ELISAs were 
run for VEGF and MMP-9 according to manufacturer's recommendations (R&D Systems). 
Physical and bioluminescent measurement of tumors in mice 
SK-ES cells stably transfected with a luciferase reporter were injected into nu/nu mice 
subcutaneously on the rear flank. Mice were then treated with a high dose (0.2mglkg) or a low 
dose (0.01mg/kg) of AJA. Each experimental group included 8 mice. 7 mice were treated with 
vehicle (DMSO) only, serving as controls. Physical tumor growth was measured in all mice 
twice per week with a caliper. Cell luminescence was also measured twice per week in all 
animals using an IVIS imaging system. In order for the tumors to luminesce, luciferin (Xenolight 
RediJect, Caliper Life Sciences) at a concentration of30mg/mL was injected into the mice at 
5J.!L per gram of body weight 30 minutes before imaging. If the tumors became too large or the 
mice lost a significant amount of weight, they were euthanized according to UAMS IACUC 
standards. 
Results 
When treated with AJA, cell viability ofTC71-PM4-GR cells was found to decrease in a 
dose-dependent manner. These results were obtained from MTT and MTS assays (FIG 1). 
Originally, MTT was the only assay being run. Hov.-e~er the results of this assay may not have 
been as accurate as possible since some of the cells ( irich gro both adherently and in 
suspension) could be vacuumed off of the plate. Th the assay was also performed. Media 
does not have to be aspirated when this assay is performed Bo: assa s showed the same general 
trend. As the concentration of AJA increased, more and re cells were killed. The LDSO, based 
on MTS data, was calculated to be 16.9J.!M. 
In the past, spheroids were created using 2 cell-lines only. One of these cell lines was an 
endothelial cell line and the other was a cancer line. Over the summer, this lab created spheroids 
using fibroblasts, a third type of cell, giving the spheroids a connective tissue component. Since 
actual tumors incorporate, are surrounded by, and must invade through connective tissue in a 
living organism, this additional component should make our spheroids a more realistic model of 
human disease. By incorporating a different color of fluorescent protein into each of the cell 
types, it will be easier to observe what is actually happening to each of the cell types when they 
are treated with AJA (FIG 2A). 
Certain proteins are required for tumor growth and invasion. Among these are vascular 
endothelial growth factor (VEGF) and matrix-metalloproteinase-9 (MMP-9). VEGF promotes 
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the formation of blood vessels to the tumor. Tumors require blood vessels in order to receive the 
nutrients they need to grow and survive. MMP-9 promotes tumor invasion by allowing the tumor 
to break down surrounding connective tissue fibers (5). Previous studies in our lab (unpublished 
data) have shown that AJA inhibits angiogenesis in an aortic ring assay as well as tumor invasion 
in vitro using modified Boyden chamber assays. When spheroids were treated with AJA and 
compared to controls, it was found that AJA decreased both of these proteins (FIG 3). However, 
initial data suggested it did not do so in a dose-dependent manner. 
The data of this study indicate that AJA inhibits tumor growth in a dose-dependent 
manner. The results for both physical tumor growth and tumor luminescence support this. 
However, the results of the data obtained are slight! ske red. While the data show an obvious 
inhibition of tumor growth in the low-dose group as compared to controls (FIG 5A&B), the data 
for the high-dose group reflect drug toxicity and ha e helped us to establish the upper limits of 
drug treatment concentrations. High-dose treatment was terminated at day 8 because weight loss 
in this group was deemed unacceptable (FIG SD) and physically the mice were lethargic and did 
not look well. Though low-dose treatment caused a slight decrease in the weight of the mice, this 
decrease was not significant enough to consider the concentration toxic or discontinue treatment. 
When the mice being treated with a higher dose of AJA stopped receiving treatment, rapid tumor 
growth was observed. 
Importantly, the results of this study indicate that there is a close ·correlation between the 
physical size of the tumor and tumor luminescence until the tumor becomes very large (FIG 5C). 
There are multiple reasons why the correlation may not be as good once the tumor becomes 
large. We favor the hypothesis that once the·tumor becomes large enough, the tumor cells 
physically have no more space for mitosis and therefore become quiescent. Our data ·support this 
hypothesis because once the tumor cells have metastasized, we again observe luminescence, this 
time in the secondary tumors. Alternatively, it is possible that once the tumor becomes too large, 
some number of cells in the tumor become necrotic because of low oxygen and nutrient 
conditions within the tumor. Dying cells would cease protein production, including luciferase 
production. It is also possible that the plasmid causing the cancer cells to produce luciferase is 
rejected over time, as there is no selective pressure in the animal for the cells to maintain it. If no 
luciferase is produced by the cancer cells, no luminescence will occur. 
Conclusions 
This study supports AJA as a possible candidate for treatment of pediatric tumors in 
the future. It has shown that this compound decreases · of Ewing's sarcoma cells in a 
dose-dependent manner. It has also brought light to so e of mechanisms by which AJA may 
be inhibiting angiogenesis and tumor invasion. Furth data produced by this study 
have given us critical information regarding the toxi · limits of the drug. Most importantly for 
our future work demonstrating the efficacy of this compound in vivo, the subcutaneous mouse 
study has shown that there is a good correlation be ;een the physical size of the tumor and 
tumor luminescence until tumors become ery large indicating that bioluminescence is a good 
model to use for studying the effects of AJA on tumors, providing the evidence we needed to 
continue use of our intratibial modeL Equall important for future studies in the lab is the 
creation of the 3-cellline spheroids produced in this study. These spheroids allow us to identify 
and study cellular pathways impacted by the drug and allow us to investigate proteins largely 
affected by the tumor microenvironment. There has previously been no realistic in vitro model in 
which to investigate these. The fluorescent proteins transfected into our cells used in the 
spheroids allow us to see the effects of our drug on the individual cell-lines; an ideal drug would 
decrease viability of the cancer cells and restrict endothelial cell proliferation, leaving the 
fibroblasts unharmed. The data provided in this study provide rationale for the use of AJA in the 
treatment of Ewing's Sarcoma and enhance biological research through the addition of critical 
model systems in which to study disease. 
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FIG 1. Cell viability is decreased in a dose-dependent manner in Ewing's sarcoma cells treated 
with AJA as compared to untreated controls. TC71-PM4-GR cells were plated and treated at the 
indicated concentrations of AJA. MTI and MTS cell viability assays were both run 72h post treatment. 
Standard errors are indicated. 
FIG 2. Spheroids were created using 2 cell-lines and 3 cell-lines. (A) EAhy-RED and 
TC71-PM4-GR cells were used to make fluorescent spheroids. (B) Endothelial Progenitor 
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FIG 3. Proteins necessary for tumor growth are decreased in spheroids treated with varying 
concentrations of AJA as compared to untreated controls. Spheroids containing Wl-38, EPC, and 
TC71-PM4-GR cells were treated with varying concentrations of AJA 6 days after being created. ELISA 
assays for VEGF and MMP-9 were performed 18h post treatment. Standard errors are indicated. 
FIG 4. A novel bioluminescent model of Ewing's sarcoma was created to study the effects of 
AJA on tumor growth. (A) SK-ES cells stably transfected with a luciferase reporter were injected into 
nu/nu mice subcutaneously. Physical tumor growth was measured in both treated and untreated mice 
twice/week with a caliper. (B) Cell luminescence was also measured twice/week in both treated and 
untreated mice using an IVIS imaging system. 
A.) 
Normalized Tumor Growth· only mice currently alive are used within 
amageu welt as mice that eventually developed a palpable tumor. 
Standard error bars added. 
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FIG 5. AJA decreases tumor growth in vivo. (A) Tumors were measured twice/week with a caliper 
to study physical growth. AJA inhibits tumor growth in a dose-dependent manner. (B) Cell 
luminescent data corresponds most closely with physical measurements in the control and low-dose 
treated mice. (C) Relationship between physical tumor growth and cell luminescence. (D) Mouse 
weight was measured 5 times/week. Low-dose treated mice weight was decreased within acceptable 
limits. Weight loss in high-dose treated mice showed evidence of drug toxicity. 
